Drugs / TIL infusion
last change Apr 2017 re-read 3 minutes ago

TIL infusion

Cell therapy

Developed for
ovarian cancer
Investigated by
Inge Marie Svane

Trials 1

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02482090 Jul 2015 → Dec 2016 ovarian cancer Inge Marie Svane Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TIL infusion ClinicalTrials.gov intervention name — accepted as the source's own label NCT02482090 ↗
Modality Cell therapy “Adoptive T cell therapy with tumor infiltrating lymphocytes (TIL)” NCT02482090 ↗